Supervised Exercise Therapy and Adjuvant Chemotherapy for Pancreatic Cancer: A Prospective, Single-Arm, Phase II Open-Label, Nonrandomized, Historically Controlled Study-Reference-Cited by-同舟云学术

Supervised Exercise Therapy and Adjuvant Chemotherapy for Pancreatic Cancer: A Prospective, Single-Arm, Phase II Open-Label, Nonrandomized, Historically Controlled Study

Published:2022-11-15 Issue:6 Volume:235 Page:848-858
ISSN:1072-7515
Container-title:Journal of the American College of Surgeons
language:en
Short-container-title:

Author:

Okada Ken-ichi,Kouda Ken,Kawai Manabu,Hirono Seiko,Miyazawa Motoki,Kitahata Yuji,Kawanishi Makoto,Natsume Yuki,Wan Ke,Yamaue Hiroki

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Surgery

Reference33 articles.

1. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.;Rahib;Cancer Res,2014

2. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.;Valle;J Clin Oncol,2014

3. Treatment strategy for borderline resectable pancreatic cancer with radiographic artery involvement.;Hirono;Pancreas,2016

4. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.;Conroy;N Engl J Med,2018

5. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.;Kharat;J Manag Care Spec Pharm,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Impact of Preoperative Osteosarcopenia for Patients with Pancreatic Ductal Adenocarcinoma After Curative Resection;Annals of Surgical Oncology;2023-07-19